Loading...

APUS APIMEDS PHARMACEUTICALS US INC Investor Conferences 8-K Filing

PMDS

PS

APIMEDS PHARMACEUTICALS US INC

(APUS)

2025 8-K

New CEO Appointment

Settlement Agreement

Delisting Notice

Filings Delay Notification

Stockholder Consent Nullified

Board Changes Invalidated

Board Restructuring

Stock Split Announcement

Director Resignations

Merger Amendment Notice

Merger Agreement

CEO Salary Increase

Bylaw Amendment

Investor Meetings

Debt Restructuring

External Links:

On July 15, 2025, Apimeds Pharmaceuticals US, Inc. issued a press release regarding company updates, which has not been specified in detail. The filing is part of their regulatory compliance under the Securities Exchange Act.

AI Assistant

APIMEDS PHARMACEUTICALS US INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.